Digital Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Digital Therapeutics, Inc. owns a portfolio of 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as PELAGO, QUIT GENIUS, and ADDICTION CARE NAVIGATOR. Of these, 7 are registered. The portfolio spans 3 Nice Classification classes, led by Class 42 (Computer & Scientific) and Class 44 (Medical Services). Headquartered in New York, NY.
350 7th Avenue, Suite 1100
New York, NY 10001
Showing of trademarks Trademarks
Trademark Classifications
Digital Therapeutics, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Digital Therapeutics, Inc. have?
Digital Therapeutics, Inc. has 7 U.S. trademarks filed with the USPTO. Of these, 7 registered.
What trademark classes does Digital Therapeutics, Inc. file in?
Digital Therapeutics, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Digital Therapeutics, Inc.'s most well-known trademarks?
Digital Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as PELAGO, QUIT GENIUS, and ADDICTION CARE NAVIGATOR. These are among 7 currently registered trademarks in the portfolio.
What is Digital Therapeutics, Inc.'s trademark registration success rate?
Digital Therapeutics, Inc. has a 100% trademark registration rate, with 7 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.